Safer Medication Use – Propranolol in the treatment of anxiety
Overview
Safer Medication Use is a bulletin series jointly produced by the Regional Drug and Therapeutics Centre and the Yellow Card Centre Northern and Yorkshire, which aims to promote safer prescribing. It discusses specific drug related safety problems, provides guidance to ensure safe, appropriate prescribing and raises awareness of adverse drug reaction detection and reporting.
Propranolol is increasingly used for the treatment of anxiety. However, several recent critical incidents have raised concerns that there may still be a lack of awareness amongst prescribers over the risks associated with propranolol in overdose. This report aims to raise awareness of the potential toxicity of propranolol in overdose and highlight a specific group of patients who may be at an increased risk of using propranolol for self-harm.
Formulary assessment – Melatonin (Adaflex) for ADHD
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
This document was updated in July 2024.
Formulary assessment – Melatonin (Ceyesto) 1mg/ml oral solution
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
The information in this document is correct at the time of publication and formulations may change. This information is produced for use by NHS healthcare professionals and RDTC stakeholders.